• linkedin
  • Increase Font
  • Sharebar

    How kidney Ca management strategies compare


    In patients with locoregional renal cell carcinoma (RCC) who were at high risk of tumor recurrence after nephrectomy, adjuvant sunitinib (Sutent) showed a 2-year advantage in median survival versus placebo.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available